Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations

Multiple Cancer Types

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral
covalent menin inhibitor, in adult patients with acute myeloid leukemia, acute lymphocytic
leukemia with KMT2A/ MLL1r, NPM1 and other mutations.
Leukemia, Phase I
I
Kishtagari, Ashwin
NCT05153330
VICCHEMP2195

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: